BETNOVATE CREAM 0.1% W/W [SIN08247P]
Active ingredients: BETNOVATE CREAM 0.1% W/W
Last updated 24 April 2026
Product Info
BETNOVATE CREAM 0.1% W/W
[SIN08247P]
Product information
Active Ingredient and Strength | BETAMETHASONE VALERATE EQV BETAMETHASONE - 0.1% W/W |
Dosage Form | CREAM |
Manufacturer and Country | GLAXO WELLCOME OPERATIONS - UNITED KINGDOM |
Registration Number | SIN08247P |
Licence Holder | GLAXOSMITHKLINE PTE LTD |
Forensic Classification | PRESCRIPTION ONLY MEDICINES |
Anatomical Therapeutic Chemical (ATC) code | D07AC01 |
Prescription-only Medicines with Exemptions for Supply without Prescription | As a topical preparation (as valerate or dipropionate salt) as a single agent not exceeding 0.1%
|
Indication
Indications
Eczema including atopic, infantile, and discoid eczemas
Prurigo nodularis
Psoriasis (excluding widespread plaque psoriasis)
Neurodermatoses including lichen simplex, lichen planus
Seborrhoeic dermatitis
Contact sensitivity reactions
Discoid lupus erythematosus
An adjunct to systemic steroid therapy in generalised erythroderma
Insect bite reactions
Prickly heat
Dosing
Dosage and Administration
A small quantity should be applied to the affected area two or three times daily until improvement occurs. It may then be possible to maintain improvement by applying once a day, or even less often.
BETNOVATE creams are especially appropriate for moist or weeping surfaces and BETNOVATE ointments for dry, lichenified or scaly lesions, but this is not invariably so.
In the more resistant lesions, such as the thickened plaques of psoriasis on elbows and knees, the effect of BETNOVATE can be enhanced, if necessary, by occluding the treatment area with polythene film. Overnight occlusion only is usually adequate to bring about a satisfactory response in such lesions thereafter, improvement can usually be maintained by regular application without occlusion.
Children
BETNOVATE is contraindicated in children under one year of age.
Children are more likely to develop local and systemic side effects of topical corticosteroids and, in general, require shorter courses and less potent agents than adults.
Care should be taken when using BETNOVATE to ensure the amount applied is the minimum that provides therapeutic benefit.
Elderly
The greater frequency of decreased hepatic or renal function in the elderly may delay elimination if systemic absorption occurs. Therefore the minimum quantity should be used for the shortest duration to achieve the desired clinical benefit.
Renal / Hepatic Impairment
In case of systemic absorption (when application is over a large surface area for a prolonged period) metabolism and elimination may be delayed therefore increasing the risk of systemic toxicity. Therefore the minimum quantity should be used for the shortest duration to achieve the desired clinical benefit.
Contraindications
Contraindications
The following conditions should not be treated with BETNOVATE:
Rosacea
Acne vulgaris
Perioral dermatitis
Perianal and genital pruritus
Pruritus without inflammation
Primary cutaneous viral infections (e.g. herpes simplex, chickenpox)
Hypersensitivity to any ingredient of the preparation
The use of BETNOVATE skin preparations is not indicated in the treatment of primarily infected skin lesions caused by infection with fungi or bacteria. BETNOVATE is contraindicated in dermatoses in infants under one year of age, including dermatitis.